Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 19:12:684015.
doi: 10.3389/fimmu.2021.684015. eCollection 2021.

Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets

Affiliations
Case Reports

Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets

Fatima A H Al-Jaberi et al. Front Immunol. .

Abstract

The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), mediates its immunomodulatory effects by binding to the vitamin D receptor (VDR). Here, we describe a new point mutation in the DNA-binding domain of the VDR and its consequences for 1,25(OH)2D3 signaling in T cells from heterozygous and homozygous carriers of the mutation. The mutation did not affect the overall structure or the ability of the VDR to bind 1,25(OH)2D3 and the retinoid X receptor. However, the subcellular localization of the VDR was strongly affected and the transcriptional activity was abolished by the mutation. In heterozygous carriers of the mutation, 1,25(OH)2D3-induced gene regulation was reduced by ~ 50% indicating that the expression level of wild-type VDR determines 1,25(OH)2D3 responsiveness in T cells. We show that vitamin D-mediated suppression of vitamin A-induced gene regulation depends on an intact ability of the VDR to bind DNA. Furthermore, we demonstrate that vitamin A inhibits 1,25(OH)2D3-induced translocation of the VDR to the nucleus and 1,25(OH)2D3-induced up-regulation of CYP24A1. Taken together, this study unravels novel aspects of vitamin D signaling and function of the VDR in human T cells.

Keywords: HVDRR; T cells; vitamin A; vitamin D; vitamin D receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The R80W mutation abolishes the transcriptional activity without affecting the structure or expression of VDRR80W (A) Localization of the C238T mutation to exon 3 in the VDR gene resulting in the R80W in the C-terminal part of the second zinc finger in the DBD of the VDR. The amino acids surrounding the R80 in the VDR from different species with the R80W at the bottom. (B) Family tree where circles represent females, squares represent males, homozygous VDRR80W marked as filled black, heterozygous VDRWT/R80W marked as filled black and white, and homozygous VDRWT marked as filled white. (C, D) In silico structure of the zinc fingers of the VDR interacting with DNA. (C) VDRWT with the R80 in red and with the hydrogen bonds between R80 and the DNA backbone indicated as blue lines. (D) The same region of VDRR80W with the W80 in blue. (E) VDR mRNA, (F) VDR protein and (G) CYP24A1 mRNA in VDRWT (black circles) and VDRR80W (white squares) CD4+ T cells activated in the presence of the indicated concentration of 25(OH)D3. (E–G) The expression levels are given as fold change normalized to the average expression level of VDRWT in control cells activated in the absence of 25(OH)D3. (E) Mean ± SD (VDRWT n = 6; VDRR80W n = 1). (F) Relative VDR protein expression as determined by the density of the VDR bands from Western blotting analysis of VDRWT and VDRR80W. The upper panel gives the density of VDRR80W (white squares) normalized to the average density of VDRWT (black circles) from control cells. The lower panel shows one representative Western blotting analysis out of five independent experiments of VDR and GAPDH (loading control) from three controls and the patient. Mean + SD (VDRWT n = 13; VDRR80W n = 1 repeated 5 times). (G) Mean ± SD (VDRWT n = 3; VDRR80W n = 1). n.s. means not significant.
Figure 2
Figure 2
The R80W mutation abolishes normal 1,25(OH)2D3-mediated gene up- and down-regulation Regularized log2 normalized gene expression in (A) VDRWT and (B) VDRR80W CD4+ T cells activated in the presence or absence of 25(OH)D3. The red and blue lines indicate the 1.5-fold threshold for up- and down-regulated genes, respectively. Genes that are at least 1.5-fold up- or down-regulated by 25(OH)D3 are colored red or blue, respectively, and the number of genes up- or down-regulated by 25(OH)D3 is indicated in the respective corners. Heatmap of genes up- (C) and down-regulated (D) by 25(OH)D3 in VDRWT CD4+ T cells. Selected genes are indicated to the right of the heatmaps. (E) CYB27B1 mRNA and (F) 1,25(OH)2D3 production in VDRWT (black circles) and VDRR80W (white squares) CD4+ T cells activated in the presence of the indicated concentration of 25(OH)D3. (E) The expression levels are given as fold change normalized to the average expression level of VDRWT in control cells activated in the absence of 25(OH)D3. Mean ± SD (VDRWT n = 6; VDRR80W n = 1). (F) Mean ± SD (VDRWT n = 6; VDRR80W n = 1).
Figure 3
Figure 3
The R80W mutation does not affect binding to 1,25(OH)2D3 and RXR but significantly affects the subcellular localization of VDRR80W (A) Relative VDR protein expression as determined by the density of the VDR bands from Western blotting analysis of VDRWT and VDRR80W CD4+ T cells activated in the absence (-) or presence (+) of 1,25(OH)2D3 (10 nM). The upper panel gives the density of VDRWT (black circles) and VDRR80W (white squares) normalized to the average density of the VDRWT bands from control cells activated in the absence of 1,25(OH)2D3. The lower panel shows one representative Western blotting analysis out of five independent experiments of VDR and GAPDH (loading control) from control and patient cells. Mean ± SD (VDRWT n = 13; VDRR80W n = 1 repeated 5 times; *p < 0.05). (B–D) Subcellular localization of VDRWT and VDRR80W in CD4+ T cells activated in (B) the absence (-) or presence (+) of 1,25(OH)2D3 (10 nM) and in (C, D) the absence (-) or presence (+) of RA (1 µM) and 1,25(OH)2D3 (10 nM). The upper panels show the fraction of VDR located to the nucleus and the cytosol in grey and black columns, respectively, as determined by the density of the VDR bands from the Western blots. The lower panels show one representative Western blotting analysis of VDR and GAPDH (loading control) from the cytosolic (C) and nuclear (N) fraction of CD4+ T cells activated in the absence (-) or presence (+) of 1,25(OH)2D3 and RA as indicated. (B) Mean ± SD (VDRWT n = 14; VDRR80W n = 1 repeated 5 times; *p < 0.05). (C, D) Mean ± SD (VDRWT n = 8; VDRR80W n = 1 repeated 3 times; *p < 0.05). (E) Relative mRNA expression of CYP24A1 in VDRWT (black circles) and VDRR80W (white squares) CD4+ T cells activated in the absence (-) or presence (+) of RA (1 µM) and 1,25(OH)2D3 (10 nM). The expression levels are given as fold change normalized to the average expression level of CYP24A1 in control cells activated in the absence of RA and 1,25(OH)2D3. Mean ± SD (VDRWT n = 6; VDRR80W n = 1 repeated twice; *p < 0.05).
Figure 4
Figure 4
Reduced responsiveness to 1,25(OH)2D3 in T cells from heterozygous family members (A) Subcellular localization of the VDR in VDRWT/R80W heterozygous CD4+ T cells activated in the absence (-) or presence (+) of 1,25(OH)2D3 (10 nM). The upper panel shows the fraction of VDR located to the nucleus and the cytosol in grey and black columns, respectively, as determined by the density of the VDR bands from the Western blotting analysis. The lower panels show one representative Western blotting analysis out of four independent experiments of VDR and GAPDH (loading control) from the cytosolic (C) and nuclear (N) fraction. Mean ± SD (VDRWT/R80W n = 4; #p < 0.05). (B) CYP24A1 and (C) CD38 mRNA expression, (D) CD38 cell surface expression, (E) IFN-γ and (F) IL-13 production in VDRWT (black circles), VDRWT/R80W (gray triangles) and VDRR80W (white squares) CD4+ T cells activated in the presence of the indicated concentration of 1,25(OH)2D3. The expression levels are given as fold change normalized to the average expression level of the given molecule in cells activated in the absence of 1,25(OH)2D3 in each group. Mean ± SD (VDRWT n = 13; VDRWT/R80W n = 4; VDRR80W n = 1; *VDRWT p < 0.05 compared to VDRWT in the absence of 1,25(OH)2D3, #VDRWT/R80W p < 0.05 compared to VDRWT/R80W in the absence of 1,25(OH)2D3).
Figure 5
Figure 5
The R80W mutation abolishes 1,25(OH)2D3-mediated suppression of RA-induced gene up-regulation Relative mRNA expression of (A) α4, (B) β7, (C) CCR9, (D) VDR and (E) LZTFL1 in VDRWT (black circles) and VDRR80W (white squares) CD4+ T cells activated in the absence (-) or presence (+) of RA (1 µM) and 1,25(OH)2D3 (10 nM). The expression levels are given as fold change normalized to the average expression level of the target gene in each group activated in the absence of RA and 1,25(OH)2D3. Mean ± SD (VDRWT n = 6; VDRR80W n = 1 repeated twice; *p < 0.05).

Similar articles

Cited by

References

    1. Mora JR, Iwata M, von Andrian UH. Vitamin Effects on the Immune System: Vitamins A and D Take Centre Stage. Nat Rev Immunol (2008) 8(9):685–98. 10.1038/nri2378 - DOI - PMC - PubMed
    1. Kongsbak M, Levring TB, Geisler C, von Essen MR. The Vitamin D Receptor and T Cell Function. Front Immunol (2013) 4:148. 10.3389/fimmu.2013.00148 - DOI - PMC - PubMed
    1. Kongsbak M, von Essen MR, Levring TB, Schjerling P, Woetmann A, Odum N, et al. . Vitamin D-binding Protein Controls T Cell Responses to Vitamin D. BMC Immunol (2014) 15:1–13. 10.1186/s12865-014-0035-2 - DOI - PMC - PubMed
    1. Rode AKO, Kongsbak M, Hansen MM, Lopez DV, Levring TB, Woetmann A, et al. . Vitamin D Counteracts Mycobacterium Tuberculosis-Induced Cathelicidin Downregulation in Dendritic Cells and Allows Th1 Differentiation and IFNgamma Secretion. Front Immunol (2017) 8:656. 10.3389/fimmu.2017.00656 - DOI - PMC - PubMed
    1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. . The Nuclear Receptor Superfamily: The Second Decade. Cell (1995) 83(6):835–9. 10.1016/0092-8674(95)90199-X - DOI - PMC - PubMed

Publication types